New treatments for botulism (botulinum toxin poisoning)
Novel therapeutic approaches to treatment of botulinum neurotoxin poisoning
Developing a new antidote that could stop the nerve-blocking effects of botulinum toxin for people with life-threatening botulism.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11115601 on NIH RePORTER |
What this research studies
This project develops a new class of antidotes that use the toxin's own nerve-cell receptors and transport pathways to reach and neutralize the toxin inside nerve terminals. Researchers will design and test molecules in laboratory and animal models to block the botulinum light chain where it stops nerve signaling. The approach aims to go beyond current antibody therapies that cannot reverse established paralysis by finding treatments that restore breathing and movement after symptoms begin. If preclinical safety and effectiveness are shown, the work could progress toward human testing.
Who could benefit from this research
Good fit: People with confirmed or suspected botulinum toxin exposure who are developing or have early signs of paralysis, especially respiratory muscle weakness, would be likely candidates when human trials begin.
Not a fit: People with paralysis from other causes, very mild cases that do not progress, or those whose nerve damage is too advanced may not benefit from this specific antidote.
Why it matters
Potential benefit: If successful, it could shorten or reverse paralysis from botulism and reduce the need for long-term mechanical ventilation.
How similar studies have performed: Existing antibody treatments can prevent progression if given early but do not reverse established paralysis, so this receptor-trafficking approach is novel and largely untested in humans.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Ichtchenko, Konstantin — New York University School of Medicine
- Study coordinator: Ichtchenko, Konstantin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.